Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences - Feb 26, 2021

26 Feb 2021
www.biospace.com
Orphan DrugBreakthrough TherapyFirst in ClassFast Track
Feb. 26, 2021 13:00 UTC CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor conferences: Cowen 41st Annual Health Care Conference on Tuesday, March 2, 2021. Management will participate in a Microbiome panel discussion as well as 1x1 meetings. Chardan 3rd Annual Microbiome Medicines Summit on Monday, March 8, 2021. Management will present a corporate overview at 2:30 p.m. ET and participate in 1x1 meetings. An audio webcast of the Chardan Summit presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days. About Seres Therapeutics Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit . View source version on businesswire.com: Contacts PR Contact Kristin Ainsworth kainsworth@serestherapeutics.com IR Contact Carlo Tanzi, Ph.D. ctanzi@serestherapeutics.com Source: Seres Therapeutics, Inc. View this news release online at:
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.